Clinics in Dermatology
Volume 27, Issue 1 , Pages 3-9 , January 2009

Melanoma epidemiology and trends

References 

  1. Jemal A, Devesa SS, Hartge P, et al. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93:678–683
  2. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol. 2001;14:280–290
  3. Black RJ, Bray F, Ferlay J, et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997;33:1075–1107
  4. Marks R. Epidemiology of melanoma. Clin Exp Dermatol. 2000;25:459–463
  5. Geller AC, Miller DR, Annas GD, et al. Melanoma incidence and mortality among US whites, 1969–1999. JAMA. 2002;288:1719–1720
  6. Globocan 2000 . 5th ed.. Globocan 2000: cancer incidence, mortality and prevalence worldwide. ARC Cancerbase. Vol 1.0. Lyon: IARC Press; 2001;
  7. Mackie RM, Hole D, Hunter JA, et al. Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979–94. The Scottish Melanoma Group. BMJ. 1997;315:1117–1121
  8. Mansson-Brahme E, Johansson H, Larsson O, et al. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976–1994. Acta Oncol. 2003;41:138–146
  9. de Vries E, Bray FI, Coebergh JW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer. 2003;107:119–126
  10. Anonymus . Stat bite: incidence of and mortality from melanoma of the skin, 1975–2000. J Natl Cancer Inst. 2003;95:933
  11. Robert Koch-Institut . Cancer in Germany 2003–2004. Frequencies and trends. Berlin: Druckhaus Berlin Mitte; 2008;[German]
  12. Bulliard JL, Cox B, Semenciw R. Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969–93. Cancer Causes Control. 1999;10:407–416
  13. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol. 1999;135:275–280
  14. Hall HI, Miller DR, Rogers JD, et al. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol. 1999;40:35–42
  15. Marrett LD, Nguyen HL, Armstrong BK. Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983–1996. Int J Cancer. 2001;92:457–462
  16. Osterlind A, Hou-Jensen K, Moller JO. Incidence of cutaneous malignant melanoma in Denmark 1978–1982. Anatomic site distribution, histologic types, and comparison with non-melanoma skin cancer. Br J Cancer. 1988;58:385–391
  17. Balzi D, Carli P, Giannotti B, et al. Cutaneous melanoma in the Florentine area, Italy: incidence, survival and mortality between 1985 and 1994. Eur J Cancer Prev. 2003;12:43–48
  18. Ocana-Riola R, Martinez-Garcia C, Serrano S, et al. Population-based study of cutaneous malignant melanoma in the Granada province (Spain), 1985–1992. Eur J Epidemiol. 2002;17:169–174
  19. MacLennan R, Green AC, McLeod GR, et al. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst. 1992;84:1427–1432
  20. Jones WO, Harman CR, Ng AK, et al. Incidence of malignant melanoma in Auckland, New Zealand: highest rates in the world. World J Surg. 1999;23:732–735
  21. Balzi D, Carli P, Geddes M. Malignant melanoma in Europe: changes in mortality rates (1970–90) in European Community countries. Cancer Causes Control. 1997;8:85–92
  22. Stang A, Stang K, Stegmaier C, et al. Skin melanoma in Saarland: incidence, survival and mortality 1970–1996. Eur J Cancer Prev. 2001;10:407–415
  23. Bulliard JL, Cox B. Cutaneous malignant melanoma in New Zealand: trends by anatomical site, 1969–1993. Int J Epidemiol. 2000;29:416–423
  24. Insinga RP, Reither EN, Remington PL, et al. Trends in malignant melanoma incidence and mortality in Wisconsin, 1979–1997. WMJ. 1902;100:27–31
  25. Gaudette LA, Altmayer CA, Wysocki M, et al. Cancer incidence and mortality across Canada. Health Rep. 1998;10:51–66
  26. Bosetti C, La Vecchia C, Naldi L, et al. Mortality from cutaneous malignant melanoma in Europe. Has the epidemic levelled off?. Melanoma Res. 2004;14:301–309
  27. Crocetti E, Carli P. Changes from mid-1980s to late 1990s among clinical and demographic correlates of melanoma thickness. Eur J Dermatol. 2003;13:72–75
  28. van der Spek-Keijser LM, van der Rhee HJ, Toth G, et al. Site, histological type, and thickness of primary cutaneous malignant melanoma in western Netherlands since 1980. Br J Dermatol. 1997;136:565–571
  29. Garbe C, McLeod GR, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer. 2000;89:1269–1278
  30. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634
  31. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484–1491
  32. Eigentler TK, Buettner PG, Leiter U, et al. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer staging system: an analysis of the German Central Malignant Melanoma Registry. J Clin Oncol. 2004;22:4376–4383
  33. Leiter U, Buettner PG, Eigentler TK, et al. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. J Clin Oncol. 2004;22:3660–3667
  34. Buettner PG, Leiter U, Eigentler TK, et al. Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer. 2005;103:616–624
  35. Buttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer. 1995;75:2499–2506
  36. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer. 1995;75:2492–2498
  37. Marks R. The changing incidence and mortality of melanoma in Australia. Recent Results Cancer Res. 2002;160:113–121
  38. Mackie RM, Bray CA, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet. 2002;360:587–591
  39. Green A, MacLennan R, Youl P, et al. Site distribution of cutaneous melanoma in Queensland. Int J Cancer. 1993;53:232–236
  40. Carli P, Borgognoni L, Biggeri A, et al. Incidence of cutaneous melanoma in the centre of Italy: anatomic site distribution, histologic types and thickness of tumour invasion in a registry-based study. Melanoma Res. 1994;4:385–390
  41. Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol. 2006;155:771–777
  42. Whiteman DC, Stickley M, Watt P, et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol. 2006;24:3172–3177
  43. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–2147
  44. Buettner P, Garbe C, Guggenmoos-Holzmann I. Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. J Clin Epidemiol. 1997;50:1201–1210
  45. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  46. Swetter SM, Soon S, Harrington CR, et al. Effect of health care delivery models on melanoma thickness and stage in a university-based referral center: an observational pilot study. Arch Dermatol. 2007;143:30–36
  47. Richard MA, Grob JJ, Avril MF, et al. Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol. 1999;135:269–274
  48. Baade PD, English DR, Youl PH, et al. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Arch Dermatol. 2006;142:1422–1427
  49. Bono A, Tolomio E, Bartoli C, et al. Metamorphosis of melanoma. Trends in size and thickness of cutaneous melanoma over one decade at the Istituto Nazionale Tumori, Milan. Tumori. 2008;94:11–13
  50. Garbe C, Wiebelt H, Orfanos CE. Change of epidemiological characteristics of malignant melanoma during the years 1962–1972 and 1983–1986 in the Federal Republic of Germany. Dermatologica. 1989;178:131–135
  51. Garbe C, Orfanos CE. Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society. Pigment Cell Res. 1992;(Suppl 2):285–294
  52. Lasithiotakis K, Leiter U, Meier F, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008;112:1795–1804
  53. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene. 2003;22:3099–3112
  54. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45–60
  55. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer. 1997;73:198–203
  56. Garbe C. The sun and malignant melanoma (German language). Hautarzt. 1992;43:251–257
  57. McGovern VJ, Mackie BS. The relationship of solar radiation to melanoblastoma. Aust N Z J Surg. 1959;28:257–262
  58. McGovern VJ Epidemiological aspects of melanoma: a review. Pathology. 1977;9:233–241
  59. Dobson AJ, Leeder SR. Mortality from malignant melanoma in Australia: effects due to country of birth. Int J Epidemiol. 1982;11:207–211
  60. Longstreth J Cutaneous malignant melanoma and ultraviolet radiation: a review. Cancer Metastasis Rev. 1988;7:321–333
  61. Hinds MW, Kolonel LN. Malignant melanoma of the skin in Hawaii, 1960–1977. Cancer. 1980;45:811–817
  62. Elwood JM, Gallagher RP, Hill GB, et al. Pigmentation and skin reaction to sun as risk factors for cutaneous melanoma: Western Canada Melanoma Study. Br Med J (Clin Res Ed). 1984;288:99–102
  63. Osterlind A, Tucker MA, Stone BJ, et al. The Danish case-control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer. 1988;42:319–324
  64. Green A, MacLennan R, Siskind V. Common acquired naevi and the risk of malignant melanoma. Int J Cancer. 1985;35:297–300
  65. Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol. 1987;17:459–468
  66. Garbe C, Buttner P, Weiss J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994;102:695–699
  67. Gallagher RP, McLean DI, Yang CP, et al. Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children. Similarities to melanoma: the Vancouver Mole Study. Arch Dermatol. 1990;126:770–776
  68. Garbe C, Buttner P, Weiss J, et al. Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994;102:700–705
  69. Harrison SL, MacLennan R, Speare R, Wronski I. Sun exposure and melanocytic naevi in young Australian children. Lancet. 1994;344:1529–1532
  70. Bauer J, Buttner P, Wiecker TS, Luther H, Garbe C. Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children. Int J Cancer. 2005;115:121–126
  71. Wiecker TS, Luther H, Buettner P, et al. Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood: a risk factor study in 1,812 kindergarten children. Cancer. 2003;97:628–638
  72. Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res. 2003;16:297–306
  73. Kumar R, Angelini S, Snellman E, et al. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol. 2004;122:342–348
  74. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19–20
  75. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol. 2003;121:1160–1162
  76. Gilchrest BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med. 1999;340:1341–1348
  77. Rieger E, Soyer HP, Garbe C, et al. Overall and site-specific risk of malignant melanoma associated with nevus counts at different body sites: a multicenter case-control study of the German Central Malignant-Melanoma Registry. Int J Cancer. 1995;62:393–397
  78. Diffey BL. The future incidence of cutaneous melanoma within the UK. Br J Dermatol. 2004;151:868–872
  79. de Vries E, van de Poll-Franse LV, Louwman WJ, et al. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol. 2005;152:481–488
  80. Whiteman DC, Bray CA, Siskind V, et al. Changes in the incidence of cutaneous melanoma in the west of Scotland and Queensland, Australia: hope for health promotion?. Eur J Cancer Prev. 2008;17:243–250
  81. Lasithiotakis KG, Leiter U, Gorkievicz R, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer. 2006;107:1331–1339

PII: S0738-081X(08)00178-8

doi: 10.1016/j.clindermatol.2008.09.001

Clinics in Dermatology
Volume 27, Issue 1 , Pages 3-9 , January 2009

Article Tools

* Image Usage & Resolution